消瘤平移合剂抗肿瘤术后转移的临床及实验研究

针对肿瘤术后患者正虚血瘀、余毒未清之病机特点，拟定益气活血、解毒散结之消瘤平移合剂。临床与化疗结合应用，观察了对Ⅱ～Ⅲａ期（Ⅲａ期为主）肿瘤术后患者近期（１年）远处转移及原位复发的影响，并与单纯化疗作对照。结果表明，肺癌、胃癌、乳腺癌转移率各观察组分别为１１．１１％，０，１０．００％，显著低于各对照组的５８．３３％，３３．３３％，４５．４５％（Ｐ＜０．０５～０．０１）；复发率观察组分别为２７．７８％，１２．５０％，１５．５０％，显著低于各对照组的６６．６７％，５５．５６％，５４．５５％（Ｐ均＜０．０５）。动物实验亦证实，消瘤平移合剂对小鼠Ｌｅｗｉｓ肺癌、Ｈ２２肝癌（术后）自发性肺和淋巴结的转移率和转移程度，皮下移植瘤及肺转移瘤的生长均有显著抑制作用。并从免疫、微循环、血液流变学、ＴＸＢ２／６－Ｋ－ＰＧＦ１α比值、癌细胞核ＤＮＡ含量及形态参数、ＡｇＮＯＲ数目及细胞周期等角度探讨了其疗效机制。

Clinical and Experimental Study on Xiaoliu Pingyi Mixture Inhibiting Tumor Metastasis of Postoperation Patients

In view of postoperative tumor patients’ pathogenesis characteristics of body resistance weakened and blood stagnated while toxic materials having not been cleared,XiaoLiu Pingyi mixture was composed for supplementing Qi,activating blood circulation,detoxicating and resolving masses In clinical study,the patients in stage of Ⅱ or Ⅲ a whose tumor relapsed or metastasized in one year were treated with Xiaoliu Pingyi mixture plus chemotherapy,compared with the control group which patients were treated with chemotherapy merely The results showed the rates of metastasis of pulmonary carcinoma,carcinoma ventriculi and mammary cancer in the observation group were 11 11%,0,10 00%,which were markedly lower than those in the control group(58 33%,33 33%,45 45%,P<0 05 or P<0 01) The recurrence rates in the observation group were 27 78%,12 50%,15 50% while those in the control group 66 67%,55 56%,54 55%(P<0 05) In experimental study,the results showed Xiaoliu Pingyi mixture cut down the ratio of the spontaneous in lung and lymph nodes of Lewis pulmonary carcinoma or H 22 hpatic carcinoma in mice and inhibitited the growth of implanted subcutaneous tumor or metastasis tumor of mice significantly